Panacea Biotec Limited — Board Meeting, 14-08-2025: Outcome of Board Meeting

Panacea Biotec's board has approved the financial results for the quarter ended June 30, 2025. Consolidated revenue from operations stood at ₹166.70 Cr. The company reported a net profit of ₹3.96 Cr, significantly boosted by an exceptional income of ₹11.32 Cr. This exceptional boost includes ₹8.58 Cr from a settlement with Apotex Inc. and ₹2.74 Cr from deferred consideration of a previous domestic pharma brand sale. Investors should note the 41st Annual General Meeting (AGM) is scheduled for September 30, 2025.